Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Ronald F Tutrone"'
Autor:
Kim N Chi, Neil Fleshner, Vincenzo Emanuele Chiuri, Siska Van Bruwaene, Jason Hafron, Douglas G McNeel, Peter De Porre, Raymond Scott Maul, Mahesh Daksh, Xiaogang Zhong, Gary E Mason, Ronald F Tutrone
Publikováno v:
The Oncologist. 28:e309-e312
Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b689a1fdfe304041fa31fc2b670b965
https://doi.org/10.1093/oncolo/oyad008
https://doi.org/10.1093/oncolo/oyad008
Autor:
Neal D. Shore, Murilo de Almeida Luz, Ugo De Giorgi, Martin Gleave, Geoffrey T. Gotto, Gabriel P. Haas, Miguel Ramirez-Backhaus, Antti Rannikko, Jamal Tarazi, Swetha Sridharan, Jennifer Sugg, Yiyun Tang, Ronald F. Tutrone, Balaji Venugopal, Arnauld Villers, Henry H. Woo, Fabian Zohren, Stephen J. Freedland
Publikováno v:
Journal of Urology. 209
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12b67b75382eb9d5276e4177feea36c4
https://doi.org/10.1097/ju.0000000000003361.09
https://doi.org/10.1097/ju.0000000000003361.09
Autor:
Howard I. Scher, Margaret K. Yu, Carla J. de Boer, Edna Chow Maneval, Rajesh Bandekar, Ralph J. Hauke, Mansoor Saleh, Charles J. Ryan, Joshi J. Alumkal, Ronald F. Tutrone, Neal D. Shore, Emmanuel S. Antonarakis, Dana E. Rathkopf
Study design (A) and patient disposition (B); data cutoff December 31, 2014.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c300df8bcc216729a178ba406f6e1c63
https://doi.org/10.1158/1078-0432.22466345.v1
https://doi.org/10.1158/1078-0432.22466345.v1
Autor:
Howard I. Scher, Margaret K. Yu, Carla J. de Boer, Edna Chow Maneval, Rajesh Bandekar, Ralph J. Hauke, Mansoor Saleh, Charles J. Ryan, Joshi J. Alumkal, Ronald F. Tutrone, Neal D. Shore, Emmanuel S. Antonarakis, Dana E. Rathkopf
Purpose: To evaluate the efficacy of apalutamide before or after treatment with abiraterone acetate and prednisone (AAP) in patients with progressive metastatic castration-resistant prostate cancer (mCRPC).Experimental Design: Two cohorts were studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a57f2fb7436a220c45f1386b1764375
https://doi.org/10.1158/1078-0432.c.6526292.v1
https://doi.org/10.1158/1078-0432.c.6526292.v1
Autor:
Michael J. Donovan, Ronald F. Tutrone, Johan Skog, Christian Fischer, James M. McKiernan, Vasisht Tadigotla, Mikkel Noerholm, Gordon D. Brown, Erik Margolis, Alan W. Partin, Ballentine Carter, Phillipp Torkler
Publikováno v:
Prostate Cancer and Prostatic Diseases. 25:296-301
Background The ability to discriminate indolent from clinically significant prostate cancer (PC) at the initial biopsy remains a challenge. The ExoDx Prostate (IntelliScore) (EPI) test is a noninvasive liquid biopsy that quantifies three RNA targets
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea34377bfccb69b425966af69e7e1c58
https://doi.org/10.1038/s41391-021-00456-8
https://doi.org/10.1038/s41391-021-00456-8
Autor:
Christopher M. Dixon, Richard M. Levin, Christopher H. Cantrill, Mikhail Regelman, Benjamin Spilseth, Ronald F. Tutrone Jr., Michael A. White, Aaron J. Milbank, Christopher A. Warlick
Publikováno v:
Journal of endourology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73ba528c478f1c8b735a2c6300084765
https://pubmed.ncbi.nlm.nih.gov/36310434
https://pubmed.ncbi.nlm.nih.gov/36310434
Publikováno v:
Clinical Genitourinary Cancer. 18:416-422
Background Numerous globally approved castration-resistant prostate cancer (CRPC) therapies are available. Enzalutamide and radium 223 (Ra 223) are approved for survival prolongation and ability to delay radiographic progression. Both have markedly d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4b40f67766f06af5556385c3a716ee7
https://doi.org/10.1016/j.clgc.2020.02.015
https://doi.org/10.1016/j.clgc.2020.02.015
Autor:
Tom McLain, Ronald F. Tutrone, Johan Skog, James M. McKiernan, Vasisht Tadigotla, Michael J. Donovan, Mikkel Noerholm, Phillipp Torkler
Publikováno v:
Prostate Cancer and Prostatic Diseases
Background The ExoDx Prostate(IntelliScore) (EPI) test is a non-invasive risk assessment tool for detection of high-grade prostate cancer (HGPC) that informs whether to proceed with prostate biopsy. We sought to assess the impact of EPI on the decisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::082ec7a2ccac1fe642c1755daaca61ca
http://europepmc.org/articles/PMC7655505
http://europepmc.org/articles/PMC7655505
Autor:
Sheldon Freedman, James Bailen, Alan Hay, Frederick Snoy, Richard Levin, Mohamed Bidair, Kenneth Goldberg, Neal D. Shore, Susan Kalota, Ronald F. Tutrone, Jonathan I. Epstein, Steven A. Kaplan
Publikováno v:
World Journal of Urology
Purpose This study was undertaken to determine the safety and efficacy of fexapotide triflutate (FT) 2.5 mg and 15 mg for the treatment of Grade Group 1 prostate cancer. Methods Prospective randomized transrectal intraprostatic single injection FT 2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::102437b4f82242dfe77ce6634378349a
https://doi.org/10.1007/s00345-020-03127-w
https://doi.org/10.1007/s00345-020-03127-w
Autor:
Ronald F. Tutrone, Andrew J. Armstrong, Oliver Sartor, Paul F. Schellhammer, Matthew Harmon, Stephen J. Freedland, David I. Quinn, Neal D. Shore, Arif Hussain, David G. McLeod, Philip W. Kantoff, Nicholas J. Vogelzang, Matthew R. Cooperberg, Nadeem A. Sheikh, Chiledum Ahaghotu, Eric J. Small, Celestia S. Higano, David F. Penson, Elisabeth I. Heath, Nancy N. Chang, Christopher Michael Pieczonka, Bruce Brown
Publikováno v:
Prostate Cancer and Prostatic Diseases
Prostate cancer and prostatic diseases, vol 23, iss 3
Prostate cancer and prostatic diseases, vol 23, iss 3
Purpose African Americans experience greater prostate cancer risk and mortality than do Caucasians. An analysis of pooled phase III data suggested differences in overall survival (OS) between African American and Caucasian men receiving sipuleucel-T.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df74513fcaa9682c5e2bb9c293892617
http://europepmc.org/articles/PMC7423504
http://europepmc.org/articles/PMC7423504